Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Liminal BioSciences Inc. LMNL

Healthcare Biotechnology
Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed... see more

Recent & Breaking News (NDAQ:LMNL)

Prometic to report its second quarter 2018 financial results and hold conference call / webcast

Canada NewsWire August 7, 2018

Prometic receives Rare Pediatric Disease Designation from U.S. FDA for small molecule drug candidate, PBI-4050

Canada NewsWire August 7, 2018

Prometic conference call to present progress report on AGM corporate action plan

PR Newswire June 22, 2018

Prometic Presents New Data on NASH Drug Candidate PBI-4547

Canada NewsWire June 22, 2018

S&P Dow Jones Indices Announces Changes to the S&P/TSX Canadian Indices

Canada NewsWire June 8, 2018

Prometic presents new clinical data on PBI-4050 for the treatment of idiopathic pulmonary fibrosis

Canada NewsWire May 22, 2018

Prometic reports its 2018 first quarter highlights and financial results

Canada NewsWire May 15, 2018

Prometic reports on its 2018 annual and special meeting of shareholders highlights

Canada NewsWire May 10, 2018

Prometic Reports Positive Clinical Data from its Intravenous Immunoglobulin (IVIG) Pivotal Phase 3 Trial

PR Newswire April 30, 2018

Prometic Presents New PBI-4050 Clinical Data From Ongoing Alström Syndrome Phase 2 Trial

Canada NewsWire April 12, 2018

Prometic Announces Appointment of Bruce Wendel as Chief Business Development Officer

PR Newswire April 3, 2018

Prometic Reports Positive Clinical Data From Ongoing PBI-4050 Study in Alström Syndrome Patients

Canada NewsWire March 28, 2018

Prometic Reports its Q4-2017 and YE-2017 Financial Results and Provides Update on Activities

Canada NewsWire March 28, 2018

Prometic to report its Fourth Quarter and Year-End 2017 Financial Results and hold Conference Call / Webcast

Canada NewsWire March 26, 2018

Prometic receives Rare Pediatric Disease Designation from U.S. FDA for its Inter-Alpha-Inhibitor-Proteins

Canada NewsWire March 5, 2018

Prometic Announces Realignment of its Clinical Program Priorities for 2018

Canada NewsWire February 20, 2018

Prometic Announces Publication of PBI-4050's Novel Antifibrotic Mechanism of Action in American Journal of Pathology

Canada NewsWire February 16, 2018

Prometic granted orphan drug designation by FDA for Inter-Alpha-Inhibitor-Proteins for treatment of necrotizing enterocolitis (NEC)

Canada NewsWire February 15, 2018

Prometic's PBI-4050: Phase 3 Pivotal Clinical Trial Design For Idiopathic Pulmonary Fibrosis (IPF) Finalized

PR Newswire January 29, 2018

Prometic to host Key Opinion Leader meeting on novel treatments for idiopathic pulmonary fibrosis (IPF)

Canada NewsWire January 25, 2018